Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eldecalcitol shows fracture benefits in osteoporosis trial

This article was originally published in Scrip

Executive Summary

Chugai's (Roche) eldecalcitol (ED-71) has shown benefits over an existing therapy in a Japanese Phase III trial for osteoporosis. After three years, patients receiving the active vitamin D3 derivative once daily showed a significant reduction in the incidence of new vertebral bone fractures compared with once-daily alfacalcidol. This is a similar vitamin D3 prodrug, marketed by Chugai as Alfarol. The 1,087-patient trial, begun in 2004, showed a similar safety profile for the two products, the firm said. Full results will be released at a later date. Eldecalcitol is being co-developed with Taisho and is scheduled for submission next year, in a market comprising an estimated 12 million sufferers.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007819

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel